ABSTRACT
Polymorphic light eruption (PLE) is the most common immunologically mediated photodermatosis, demonstrating many abnormalities caused by critical failure of ultraviolet (UV)-induced immunosuppression. The unique expression of antimicrobial peptides in PLE, which is most likely determined by alteration of microbiome components upon UV exposure, implicates their possible triggering role and pathogenic significance in the eruption. The review aims to clarify current knowledge regarding the immunological disturbances correlated with PLE that serve a base for better understanding of molecular pathogenesis of the disease and the development of new therapeutic strategies. Preventive treatment with broad-spectrum suncreens and sunscreens containing DNA repair enzymes, as well as natural photohardening with graduate exposure to sunlight in early spring could be sufficient in milder cases. Antioxidants and topical calcipotriol are promising approach for adjuvant prevention. Phototherapy, mainly with narrow band UVB rays, is more appropriate method in severe cases of the disease. The established treatment options for PLE include local and systemic glucocorticoids, systemic nonsedative antihistamines for itch relief, and rarely, immunosuppressive drugs in the refractory cases. Like medical photohardening, afamelanotide has the potential of photoprotection by inducing a melanization of the skin. Afamelanotide is believed to be a possible new treatment option for very severe and refractory cases of PLE. Targeting the main pruritogenic cytokine, IL-31, opens a new road for the development of novel therapeutic approaches to combat moderate and severe itching in cases of PLE with intense pruritus.
Subject(s)
Photosensitivity Disorders , Humans , Photosensitivity Disorders/drug therapy , Photosensitivity Disorders/etiology , Phototherapy , Skin/pathology , Sunlight , Sunscreening Agents/therapeutic use , Ultraviolet Rays/adverse effectsABSTRACT
Background: ultraviolet radiation types A and B (UV) (400-315nm and 315-280nm respectively) are the main components present in sunlight known to cause skin injuries. Arnica montana is a plant that has been widely studied for containing anti-inflammatory, healing and analgesic properties capable of preventing or ameliorating lesions. Here, we investigated the therapeutic effect of topical application of Arnica montana after UVB-induced cutaneous injuries in mice.Methods: mice were exposed to UVB radiation (Philips TL40W/12 RS lamp) in a period of 3 hours. After one hour of radiation exposure, the animals were treated with topical application of Arnica montana ointment (250 mg/g) in the ear. At the time of 16 hours after treatment, the parameters of edema, oxidative stress and inflammatory reaction were measured in the ear of mice.Results: our results demonstrated that topical treatment with Arnica montana reduced the UVB-induced inflammatory response as demonstrated by the reduction of ear edema, inhibition of myeloperoxidase activation, decrease of nuclear factor kappa B levels and reduction of proinflammatory cytokines levels, such as interleukin-1beta, interleukin-6, tumour necrosis factor-alpha and interferon-gamma. In addition, Arnica montana ameliorated oxidative damage mediated by UVB radiation, as demonstrated by the reduction of lipid peroxidation, protein oxidation and increase of tissue antioxidant capacity and glutathione levels in the ear.Conclusion: we concluded that Arnica montana ointment is effective in alleviating the auricular inflammatory process and oxidative damage induced by acute UVB radiation, sustaining the traditional use of Arnica montana for the treatment of skin disorders.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Arnica , Edema/drug therapy , Photosensitivity Disorders/drug therapy , Plant Preparations/therapeutic use , Radiation Injuries, Experimental/drug therapy , Ultraviolet Rays/adverse effects , Animals , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Cytokines/metabolism , Edema/metabolism , Male , Mice , NF-kappa B/metabolism , Ointments , Oxidative Stress/drug effects , Peroxidase/metabolism , Photosensitivity Disorders/metabolism , Plant Preparations/pharmacology , Radiation Injuries, Experimental/metabolismABSTRACT
The efficacy of wheat extract oil (WEO), standardized to glucosylceramides, for protecting against ultraviolet B (UVB)-induced damage of skin barrier function was assessed using the SHK-1 hairless mouse model and two human skin cell lines, namely, CCD-986sk and HeCaT. The ability of repeated oral administration of 30, 60, and 120 mg of WEO/kg/day for 12 weeks to prevent skin damage of SKH-1 hairless mice induced by UVB irradiation was evaluated. The results demonstrated that UVB-induced water evaporation (transepidermal water loss, TEWL) was significantly decreased by WEO. Similarly, UVB-induced losses in moisture and skin elasticity were improved by WEO supplementation. WEO attenuated the tissue procollagen type I, hyaluronic acid (HA), and ceramide reductions induced by UVB treatment as well. Collagen concentrations in skin tissue were increased in the WEO-treated mice, while UVB-induced epidermal thickening was reduced. In vitro studies using HeCaT human keratinocytes confirmed increased HA and collagen synthesis in response to WEO treatment. This may occur via WEO suppression of matrix metallopeptidase-1 (MMP-1), since its induction by UVB treatment was diminished in treated CCD-986sk cells. Oral administration of WEO improves skin barrier function in UVB-irradiated mice by attenuating damage typically observed in photoaging. This research further clarifies the clinical benefits previously observed by dietary WEO consumption.
Subject(s)
Collagen/biosynthesis , Photosensitivity Disorders/drug therapy , Plant Oils/pharmacology , Skin Aging/drug effects , Triticum/chemistry , Animals , Humans , Keratinocytes/metabolism , Mice , Mice, Hairless , Photosensitivity Disorders/etiology , Skin Aging/radiation effects , Ultraviolet Rays/adverse effectsABSTRACT
BACKGROUND: Solar urticaria (SU) is a rare photodermatosis causing a significant impact on patients' quality of life (QoL), and treatment is often challenging. AIM: To analyse clinical experience with a tailored stepwise therapeutic approach. METHODS: A retrospective cohort design was used. Patients with suspected SU underwent laboratory investigations and photoprovocation. Those with a high minimal urticaria dose (MUD) were treated with a single antihistamine (protocol 1), and those with a lower MUD received three types of antihistamines (protocol 2); both protocols included a leucotriene receptor antagonist (LRA). In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month). Symptom relief and photoprovocation under treatment were evaluated. RESULTS: In total, 30 patients (10 men, 20 women) were enrolled. Most (87%) were sensitive to visible light (1-70 J/cm2 ) with or without extension to ultraviolet A. Of the 30 patients, 23 opted for our stepwise approach: 22 achieved complete remission on protocols 1 or 2 (n = 17) or after switching to omalizumab (n = 5), and another patient achieved partial remission under omalizumab. There were no treatment-related severe adverse effects. CONCLUSIONS: Symptoms of SU can be well controlled by treatment with antihistamines and an LRA tailored to the degree of photosensitivity, followed by omalizumab in refractory cases. This has important implications for patient QoL.
Subject(s)
Anti-Allergic Agents/therapeutic use , Histamine Antagonists/therapeutic use , Leukotriene Antagonists/therapeutic use , Omalizumab/therapeutic use , Photosensitivity Disorders/drug therapy , Urticaria/drug therapy , Acetates/therapeutic use , Adolescent , Adult , Aged , Cetirizine/therapeutic use , Child , Cohort Studies , Cyclopropanes , Disease Management , Female , Humans , Loratadine/analogs & derivatives , Loratadine/therapeutic use , Male , Middle Aged , Quinolines/therapeutic use , Retrospective Studies , Sulfides , Terfenadine/analogs & derivatives , Terfenadine/therapeutic use , Young AdultSubject(s)
PUVA Therapy/methods , Photosensitivity Disorders/drug therapy , 5-Methoxypsoralen/administration & dosage , 5-Methoxypsoralen/adverse effects , Adult , Drug Administration Schedule , Female , Humans , Male , Methoxsalen/administration & dosage , Methoxsalen/adverse effects , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/adverse effects , Retrospective StudiesABSTRACT
Se presentan 3 pacientes con urticaria solar que o no habían respondido adecuadamente o presentaban limitaciones a los tratamientos de primera línea (antihistamínicos H1 a dosis altas o fototerapia), que fueron tratados con omalizumab. Dos de ellos mejoraron clínicamente con un aumento muy importante de la tolerancia a la luz, uno de ellos con clara mejoría de la calidad de vida. El otro paciente no mejoró y desarrolló una reacción local leve a la medicación inyectada. Omalizumab puede ser por tanto una alternativa terapéutica potencialmente útil y segura en urticarias solares graves no respondedoras al tratamiento convencional (AU)
We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1 antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy (AU)
Subject(s)
Humans , Female , Middle Aged , Urticaria/drug therapy , Solar Radiation/adverse effects , Photosensitivity Disorders/drug therapy , Omalizumab/pharmacokinetics , Chronic Disease/drug therapy , Histamine Antagonists/therapeutic useABSTRACT
INTRODUCTION: Polymorphic light eruption (PLE) is a common idiopathic photodermatosis that typically presents with pruritic papular or papulovesicular lesions on sun-exposed skin between spring and autumn. In many subjects PLE is mild, and can usually be prevented by the use of broad-spectrum topical sunscreens and a gradual increase in sunlight exposure. However, in some individuals, sunlight exposure results in florid PLE and they often benefit from prophylactic desensitization treatment using phototherapy in early spring, an artificial method that induces a "hardening" phenomenon. OBJECTIVE: To describe and evaluate the efficacy of a short desensitization protocol, based on a one-month-treatment, administered twice a week with narrow band UVB in subjects with severe polymorphic light eruption (PLE). METHODS: A retrospective, open planned and non-randomized study to assess the efficacy of UVB phototherapy in prevention of polymorphic light eruption. RESULTS: Fifteen subjects diagnosed with severe PLE were treated with the standard protocol in our Photobiology Unit between 2014 and 2015. The effect of hardening was sustained during follow up in 87.5% of desensitization treatments. A statistically significant association (p<0.05) between the years of duration of the PLE and the response to treatment was found. CONCLUSIONS: The effect of hardening was maintained in the vast majority of subjects, obtaining a good benefit with no PLE episodes during all the summer. We demonstrate that our standard protocol is effective, and produces a successful outcome for the majority of PLE subjects. Our protocol is shorter than those currently applied, being favourable both for the patient and the physician.
Subject(s)
Photosensitivity Disorders/radiotherapy , Skin Diseases, Genetic/radiotherapy , Ultraviolet Therapy/methods , Adolescent , Adult , Antibodies, Antinuclear/analysis , Combined Modality Therapy , Follow-Up Studies , Histamine Antagonists/therapeutic use , Humans , Middle Aged , Photosensitivity Disorders/drug therapy , Photosensitivity Disorders/immunology , Retrospective Studies , Seasons , Skin/radiation effects , Skin Diseases, Genetic/drug therapy , Skin Diseases, Genetic/immunology , Sunlight/adverse effects , Treatment Outcome , Young Adult , beta Carotene/therapeutic useABSTRACT
We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1 antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy.
Subject(s)
Omalizumab/therapeutic use , Photosensitivity Disorders/drug therapy , Urticaria/drug therapy , Aged , Drug Evaluation , Drug Resistance , Histamine H1 Antagonists/therapeutic use , Humans , Lighting/adverse effects , Male , Middle Aged , Omalizumab/adverse effects , Photosensitivity Disorders/etiology , Photosensitivity Disorders/psychology , Phototherapy , Quality of Life , Sunlight/adverse effects , Urticaria/etiology , Urticaria/psychologyABSTRACT
The treatment of solar urticaria is regarded as difficult. In some cases good responses to the anti-IgE antibody omalizumab (Xolair®), approved for treatment of chronic spontaneous urticaria, have been reported. We report on a 50-year-old Caucasian woman who for the last 5 years has developed localized itching and stinging erythemas following exposure to sunlight accompanied sometimes by anaphylactic reactions. Oral antihistamines in three- to four-fold doses and a topical sun screen had been only partially effective in long-term use. Positive immediate-type reactions with whealing appeared in phototesting with low doses of UVB and UVA. Three weeks after s. c. injection of 300 mg omalizumab, the minimal urticarial dose (MUD) for UVB was increased at least 20-fold (from <0.001 to 0.02 J/cm2) and for UVA four-fold (from 0.1 to 0.4 J/cm2) and the patient reported no itching at the test area. On the other hand, MUD for UVA1 remained unchanged (5.0 J/cm2). The weekly urticarial activity score (UAS7) was reduced from 30 points before omalizumab administration to 14 points in weeks two and three. Overall, a partial response of solar urticaria to omalizumab therapy could be observed in the present case.
Subject(s)
Omalizumab/administration & dosage , Photosensitivity Disorders/drug therapy , Photosensitivity Disorders/etiology , Sunlight/adverse effects , Urticaria/drug therapy , Urticaria/etiology , Anti-Allergic Agents/administration & dosage , Female , Humans , Middle Aged , Photosensitivity Disorders/diagnosis , Treatment Outcome , Urticaria/diagnosisABSTRACT
Photodermatoses are a group of skin conditions associated with an abnormal reaction to ultraviolet (UV) radiation. There are several of the photosensitive rashes which mainly affect the UV exposed areas of the skin. It can be classified into four groups: immunology mediated photodermatoses, chemical and drug induced photosensitivity, photoaggravated dermatoses, and genetic disorders. A systematic approach including history, physical examination, phototesting, photopatch testing, and laboratory tests are important in diagnosis of a photodermatosis patient. In order to optimally treat a disease of photodermatoses, we need to consider which treatment offers the most appropriate result in each disease, such as sunscreens, systemic medication, topical medication, phototherapy, and others. For all groups of photodermatoses, photoprotection is one of the essential parts of management. Photoprotection, which includes sunscreening and wearing photoprotective clothing, a wide brimmed hat, and sunglasses, is important. There are also promising emerging photoprotective agents.
Subject(s)
PUVA Therapy , Photosensitivity Disorders/drug therapy , Sunscreening Agents/therapeutic use , Antimalarials/therapeutic use , Antioxidants/therapeutic use , Calcineurin Inhibitors/therapeutic use , Glucocorticoids/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Immunosuppressive Agents/therapeutic use , Mycophenolic Acid/therapeutic use , Photosensitivity Disorders/classification , Photosensitivity Disorders/etiology , Thalidomide/therapeutic use , beta Carotene/therapeutic useABSTRACT
A 52-year-old man with Fitzpatrick type V skin presented for evaluation of a photodistributed eruption of unknown origin. The patient reported a 20-year history of the dermatitis, with worsening severity during the past 6 years. He had required one hospital admission with intravenous methylprednisolone and two extended courses of oral prednisone (starting dose of 60 mg/d). He complained of pruritus and swelling localized to the sun-exposed areas of the forearms, face, and neck, with notable sparing of photoprotected areas of his skin. He denied new medications, and a systemic review of systems was noncontributory.
Subject(s)
Dermatitis/drug therapy , Dermatologic Agents/administration & dosage , Photosensitivity Disorders/drug therapy , Plant Extracts/administration & dosage , Polypodium/chemistry , Administration, Oral , Dermatitis/etiology , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Solar urticarial (SU) is characterized by erythema, whealing, and/or pruritus occurring minutes after sun exposure. Treatment is difficult and often unsatisfactory. OBJECTIVES: To determine the action spectra and minimal urticaria dose (MUD) and to tailor a treatment regimen graded according to disease severity in a series of patients with SU. PATIENTS AND METHODS: Eleven patients (seven females, four males, age range: 5-60 years) with a clinical history suggestive of SU, verified by photo-provocation tests to ultraviolet A (UVA), visible light, and/or UVB, were treated with various combinations of antihistamines and leukotriene receptor antagonist. RESULTS: All patients were sensitive to visible light (median MUD 50 J/cm(2)). Three patients were sensitive to UVA (median MUD 3.75 J/cm(2)), and one patient was sensitive to UVB (MUD of 0.03 J/cm(2)). Two patients experienced a spontaneous remission without treatment. One patient declined treatment. The remaining eight patients were managed by a combination of antihistamines (desloratidine, fexofenadine, cetirizine HCl) and a leukotriene receptor antagonist (montelukast). Seven of the 8 patients experienced a sustained remission of symptoms and signs following treatment. CONCLUSIONS: Photoprovocation for SU with determination of action spectra and MUD enables specifically tailored treatment regimens consisting of combinations of antihistamines and leukotriene receptor antagonist.
Subject(s)
Acetates/therapeutic use , Histamine H1 Antagonists, Non-Sedating/therapeutic use , Leukotriene Antagonists/therapeutic use , Photosensitivity Disorders/drug therapy , Quinolines/therapeutic use , Sunlight/adverse effects , Urticaria/drug therapy , Adolescent , Adult , Cetirizine/therapeutic use , Child , Child, Preschool , Cyclopropanes , Drug Therapy, Combination , Female , Humans , Loratadine/analogs & derivatives , Loratadine/therapeutic use , Male , Middle Aged , Photosensitivity Disorders/etiology , Remission Induction , Remission, Spontaneous , Severity of Illness Index , Sulfides , Terfenadine/analogs & derivatives , Terfenadine/therapeutic use , Ultraviolet Rays/adverse effects , Urticaria/etiology , Young AdultABSTRACT
Pseudoporphyria refers to a rare bullous dermatosis characterized by the clinical and histological features of porfiria cutanea tarda without abnormalities in porphyrin metabolism. The pathogenesis is heterogeneous and several exogenous factors may promote the bullous lesion formation, including medications, end stage renal disease, dialysis and tanning beds. Regarding treatment of this condition, in literature different therapy have been reported, such as glutathione and his precursor N-acetylcysteine, which presents anti-oxidant properties; however even more toxic drugs, such as chloroquine, are used. Moreover, in patients with drug-induced PP discontinuation of the offending agent, if possible, is a crucial aspect of the clinical management. We report two cases of dialysis patients presenting blisters on extremities, which healed with the avoidance of UV exposure and oral Vitamin D supplementation. Interestingly Vitamin D despite the lack of antioxidant properties led to a completely resolution of PP in both our patients within 30 days. A possible explanation of this finding is that Vitamin D, playing a key role in the regulation of serum Ca2+, can modulated cadherin-cadherin interactions and led to healing of pseudoporphyria bullous lesions. Finally we highlight the prominent role of UV-exposure in PP elicitation thus a good photoprotection is essential for all patients with pseudoporphyria.
Subject(s)
Photosensitivity Disorders/drug therapy , Renal Dialysis/adverse effects , Skin Diseases, Vesiculobullous/drug therapy , Sunlight/adverse effects , Ultraviolet Rays/adverse effects , Vitamin D Deficiency/complications , Vitamin D/therapeutic use , Aged , Calcium/physiology , Cosmetic Techniques/adverse effects , Desmosomal Cadherins/physiology , Diagnosis, Differential , Female , Humans , Intercellular Junctions , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Middle Aged , Nephrosclerosis/complications , Peritoneal Dialysis/adverse effects , Photosensitivity Disorders/diagnosis , Photosensitivity Disorders/etiology , Porphyria Cutanea Tarda/diagnosis , Porphyrins/analysis , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/etiology , Vitamin D/physiology , Vitamin D Deficiency/drug therapyABSTRACT
Photosensitization is a process in which the skin reacts to exposure to ultraviolet radiations. There are various associated dermatological consequences like photoxicity and photoallergic reactions which make the disease more complicated. There are various drugs which together with solar radiations worsen the situation of photosensitivity and hence termed as photosensitizers. The developments on the use of phytoconstituents from the herbal extract is the ardent need for fighting against the deleterious photosensitization reactions. This review attempts to highlight the problems of photosensitivity its pathological manifestation with the approach to treat them naturally with the help of skin rejuvenating herbs.
Subject(s)
Dermatitis, Phototoxic/drug therapy , Photosensitivity Disorders/drug therapy , Plant Extracts/pharmacology , Ultraviolet Rays/adverse effects , Humans , Photosensitizing Agents , Plants, Medicinal , Skin/drug effects , Skin/radiation effectsSubject(s)
PUVA Therapy/adverse effects , Photosensitivity Disorders/drug therapy , Tetrahydronaphthalenes/therapeutic use , Administration, Topical , Bexarotene , Follow-Up Studies , Humans , Male , Middle Aged , Mycosis Fungoides/drug therapy , Mycosis Fungoides/pathology , PUVA Therapy/methods , Photosensitivity Disorders/etiology , Risk Assessment , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Treatment OutcomeABSTRACT
BACKGROUND: Chronic actinic dermatitis (CAD) is a debilitating photodermatosis with characteristic clinical, histological and photobiological features (reduced minimal erythema dose: MED). Its management involves various therapeutic approaches, among them there is phototherapy. Efficacy of psoralen ultraviolet therapy (PUVA therapy) was previously demonstrated but there are no current data on the use of narrowband ultra violet B (UVB) therapy (NB-UVB) in CAD. NB-UVB has already been proven to be effective and safe in several other photodermatoses. CASE REPORTS: We report here two dark-skinned patients (skin type IV and V) with CAD, successfully treated with an incremental regimen of NB-UVB phototherapy coupled to a 3 month-course of systemic steroids (1mg/Kg/day). CONCLUSION: Our protocol of NB-UVB with steroids seems to be effective for the management of CAD with a good short term safety profile.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , PUVA Therapy/methods , Photosensitivity Disorders/therapy , Steroids/therapeutic use , Aged , Agricultural Workers' Diseases , Humans , Male , Middle Aged , Occupational Exposure , PUVA Therapy/adverse effects , Photosensitivity Disorders/drug therapy , Photosensitivity Disorders/radiotherapy , Prednisone/therapeutic use , Skin/pathologyABSTRACT
AIM: Idiopathic photodermatoses (IP) are a recurrent, acquired sunlight-induced rash of delayed onset, appearing after exposure to ultraviolet radiation in susceptible individuals. The aim of this study was to assess the photoprotective activity of polypodium leucotomos (PL) in IP. METHODS: Fifty-seven patients affected by IP were recruited for the study (53 with polymorphic light eruption and 4 with solar urticaria). The use of UV protection filters or other drugs that could in some way interfere with exposure to light were excluded. All patients exposed themselves to sunlight while consuming 480 mg/day of PL extract orally. A statistical evaluation of the basal clinical conditions compared to those after sunlight exposure with PL was performed. RESULTS: About 73.68% of the patients had a benefit from the administered PL, with a significant reduction of skin reaction and subjective symptoms. No side effects were observed. Results were statistically significant (P<0.05). CONCLUSION: PL complete absence of toxicity combined with its multifactorial protection, makes it an effective and safe treatment for photoprotection in IP.
Subject(s)
Photosensitivity Disorders/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Polypodium , Ultraviolet Rays/adverse effects , Administration, Oral , Adult , Aged , Algorithms , Female , Humans , Male , Middle Aged , Photosensitivity Disorders/etiology , Plant Extracts/administration & dosage , Treatment OutcomeABSTRACT
The treatment of solar urticaria (SU) can be difficult. Only a few cases of SU have been treated with intravenous immunoglobulins (IVIg) (as monotherapy or combined with phototherapy), with reported fast and durable increase of solar exposure tolerance. A 61-year-old female with severe UVB- and UVA-induced SU and a 62-year-old female with severe UVA and visible light-induced SU were both treated with a single course of IVIg (total dose of 2 g/kg), infused over 3 days. Phototest, performed 3 months after the treatment, showed only a slight minimal urticating dose improvement, and both patients reported just a moderate and 'transient' subjective improvement. Our patient's poorer response, compared with previous reports, may be due to differences in IVIg's treatment schedules, which are reviewed.
Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Photosensitivity Disorders/drug therapy , Urticaria/drug therapy , Female , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunotherapy , Middle Aged , Treatment OutcomeABSTRACT
A 66-year-old man was diagnosed with psoriasis in 2001 and treated accordingly; in 2007, the diagnosis was switched to atopic dermatitis and the therapy modified. Initially he improved with fumarates and methotrexate, but then experienced recurrent exacerbations with erythroderma and severe superinfection requiring hospitalization. Based on the modified clinical picture with striking accentuation on the head and back of the hands, we diagnosed chronic actinic dermatitis. In September 2008 immunosuppressive therapy with mycophenolate mophetil (2×500 mg/d) was started. Since the response was modest, photo-hardening with systemic photochemotherapy (PUVA) was added, producing close to complete recovery within 6 months.
Subject(s)
Immunosuppressive Agents/therapeutic use , Mycophenolic Acid/analogs & derivatives , PUVA Therapy , Photosensitivity Disorders/drug therapy , Aged , Biopsy , Drug Therapy, Combination , Humans , Intradermal Tests , Male , Mycophenolic Acid/therapeutic use , Photosensitivity Disorders/pathology , Skin/pathologyABSTRACT
Chronic actinic dermatitis (CAD) describes a condition resulting from abnormal photosensitivity; the dermatitis is clinically similar to contact allergic dermatitis. Sun-exposed skin is more commonly affected but the condition can extend to and encompass unexposed skin. CAD is relatively rare but becomes more prevalent in the elderly population. Phototesting, patch testing and laboratory results should be used to help guide diagnosis. In the elderly, it is important to distinguish CAD from drug-induced photosensitivity. Management of the condition requires sunlight avoidance and use of sunscreens, topical emollients and topical corticosteroids. Oral corticosteroids and immunosuppressive therapy such as azathioprine may be indicated but should be used with caution in the elderly.